Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Patients With SOLID TUMORS (CATCH)
Sponsor: Baylor College of Medicine
A PHASE1 clinical study on Embryonal Sarcoma of the Liver and Liposarcoma, this trial is ongoing. The trial is conducted by Baylor College of Medicine and has accumulated 11 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2025 — Mar 2026 [monthly]
Recruiting PHASE1
-
Dec 2024 — Aug 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Sep 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — May 2023 [monthly]
Recruiting PHASE1
-
May 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Feb 2022 — May 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- The Methodist Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .